3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term
These companies are in the right place at the right time with the right products.
RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
Recursion Pharmaceuticals stock drops as Q2 loss widens and pipeline shake-up continues, despite revenues boost from Sanofi milestone.
Why Recursion Pharmaceuticals Stock Tanked on Tuesday
It's common for clinical-stage biotech companies to post net losses, but the market wasn't forgiving of this one's latest.
Recursion ( RXRX ) Q2 Revenue Jumps 33%
Recursion Pharmaceuticals ( NASDAQ:RXRX ) , a technology-driven biotech company decoding biology using artificial intelligence for drug discovery, released its financial results for the second quarter of 2025 on August 5, 2025.
Recursion Pharmaceuticals Reports Wider-Than-Expected Q2 Loss, Beats Revenue Estimates - Recursion Pharmaceuticals ( NASDAQ:RXRX )
Recursion reports second-quarter revenue of $19.22 million, beating analyst estimates of $16.23 million. Recursion reports a second-quarter loss of 41 cents per share, missing estimates for a loss of 34 cents per share. The market's back, and these 3 income stocks are thriving. See them here→
Recursion Pharmaceuticals ( RXRX ) Reports Q2 Loss, Beats Revenue Estimates
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -17.14% and +33.71%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?
RXRX eyes Q2 earnings beat despite past misses, with a refocused pipeline and new data updates on key drug candidates.
2 Beaten-Down Stocks With Incredible Upside Potential
Getting in on the ground floor with these companies might lead to superior returns.
Gilead Sciences ( GILD ) Expected to Beat Earnings Estimates: Should You Buy?
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recursion Pharmaceuticals ( RXRX ) Registers a Bigger Fall Than the Market: Important Facts to Note
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $5.81, moving 2.35% from the previous trading session.
Why Recursion Pharmaceuticals ( RXRX ) Dipped More Than Broader Market Today
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.95, marking a -5.71% move from the previous day.
Why Recursion Pharmaceuticals Stock Got Mashed on Monday
Investors weren't cheered by news from one of the biotech's rivals.
The Median Retirement Savings for American Households Is $87,000. Here Are 3 Incredible Stocks to Buy Now and Hold for Decades.
You should probably be saving more, but even if you can't do that, you can get more out of the money you are able to save.
Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma - Recursion Pharmaceuticals ( NASDAQ:RXRX ) , Tempus AI ( NASDAQ:TEM ) , Palantir Technologies ( NASDAQ:PLTR )
Palantir, Tempus and Recursion are racing to reshape drug discovery with AI and data-driven platforms. Investors are watching closely as these disruptors challenge Big Pharma's traditional R&D with faster, smarter pipelines. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On
RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?
Recursion Pharmaceuticals and Relay Therapeutics both leverage their respective AI drug discovery platforms to potentially develop novel therapeutic candidates.
Recursion Pharmaceuticals ( RXRX ) Stock Drops Despite Market Gains: Important Facts to Note
Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $6.43, signifying a -1.68% move from its prior day's close.
Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses?
Recursion Pharmaceuticals bets on REC-4881, cancer candidates and new hypophosphatasia therapy to rebuild momentum after key drug cuts rattled investors.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Top 2 Health Care Stocks You May Want To Dump This Quarter - Medpace Hldgs ( NASDAQ:MEDP ) , Recursion Pharmaceuticals ( NASDAQ:RXRX )
As of July 22, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices ...
Recursion Pharmaceuticals Options Trading: A Deep Dive into Market Sentiment - Recursion Pharmaceuticals ( NASDAQ:RXRX )
Investors with a lot of money to spend have taken a bearish stance on Recursion Pharmaceuticals RXRX. We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
Is Recursion Pharmaceuticals Gaining or Losing Market Support? - Recursion Pharmaceuticals ( NASDAQ:RXRX )
Recursion Pharmaceuticals's RXRX short percent of float has fallen 8.79% since its last report. The company recently reported that it has 117.41 million shares sold short, which is 29.07% of all regular shares that are available for trading.
Why Is Recursion Pharma Stock Surging On Monday? - Recursion Pharmaceuticals ( NASDAQ:RXRX )
REC-3565, a MALT1 inhibitor developed via AI, is now in Phase 1 for blood cancers. REC-617 showed encouraging signs in a patient with recurrent ovarian cancer. A new wave of value and momentum stocks could be setting up for major moves-and Tim Melvin will name them live this Wednesday.
Galaxy Digital, Blaize Holdings, Verizon And Other Big Stocks Moving Higher On Monday - AbCellera Biologics ( NASDAQ:ABCL ) , Absci ( NASDAQ:ABSI )
U.S. stocks were higher, with the Dow Jones index gaining around 100 points on Monday. Shares of Galaxy Digital GLXY rose sharply during Monday's session after the company announced it has partnered with K Wave Media to accelerate Bitcoin treasury strategies and have access to greater ...
Recursion Pharmaceuticals ( RXRX ) Soars 5.8%: Is Further Upside Left in the Stock?
Recursion Pharmaceuticals (RXRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Recursion Pharmaceuticals ( RXRX ) Rises Higher Than Market: Key Facts
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $5.52, indicating a +2.41% shift from the previous trading day.
Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock
RXRX gains 5.5% in a month on positive pipeline update. long-term hold advised given strong potential of its AI-driven drug discovery platform.
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
RXRX is scaling its AI-driven drug discovery technology through billion-dollar pharma deals and strategic tech alliances.
Jensen Huang's Nvidia Owns 6 Stocks. Here's the Best of the Bunch.
Nvidia ( NASDAQ: NVDA ) is widely considered the ultimate pick-and-shovel play in the artificial intelligence ( AI ) space. The company's graphics processing units ( GPUs ) have become the standard for training the large language models ( LLMs ) that make AI possible.
Recursion Pharmaceuticals ( RXRX ) Surpasses Market Returns: Some Facts Worth Knowing
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.72, marking a +2.24% move from the previous day.
RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program
Recursion Pharmaceuticals stock jumps after securing full rights to REV102, aiming to fast-track the first oral therapy for hypophosphatasia.
10 Under-the-Radar Tech Stocks With Incredible Growth Potential
Just because it's not a household name doesn't mean it's not a magnificent investment.
Here's Why Shares in Recursion Pharmaceuticals Surged Today
Shares in biotech company Recursion Pharmaceuticals ( NASDAQ: RXRX ) surged by more than 12% by 11 a.m. ET today. The move is due to a de-risking event in its drug discovery pipeline.The de-risking event relates to the acquisition of the 50% interest in an ENPP1 inhibitor program ( REV102 ) that ...
Why Is Microcap Rallybio Stock Trading Higher On Tuesday? - Rallybio ( NASDAQ:RLYB ) , Recursion Pharmaceuticals ( NASDAQ:RXRX )
Rallybio receives $7.5 million upfront equity and is eligible for $17.5 million in future milestone payments. The cash runway is now extended into mid-2027 following the asset sale. From tariffs to inflation, macro risks are rising-Matt Maley reveals how he's trading it all, live this Wednesday ...
The Hottest 10 Artificial Intelligence ( AI ) Stocks on the Market
This group of companies reflects most of the industry's past, present, and future.
Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith?
Recursion Pharmaceuticals axes three drug programs after weak study data, but shifts focus to more promising candidates like REC-4881 to regain ground.
Alphabet-Backed Drug Discovery Firm Nears Human Trials Of AI-Developed Remedies, Says President: 'The Next Big Milestone Is…' - Alphabet ( NASDAQ:GOOG ) , Advanced Micro Devices ( NASDAQ:AMD )
Alphabet Inc.'s GOOG GOOGL Isomorphic Labs says its first artificial-intelligence-designed medicines are nearly ready for human testing.
Why Recursion Pharmaceuticals ( RXRX ) Outpaced the Stock Market Today
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $5.27, denoting a +1.15% move from the preceding trading day.
Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process?
Recursion Pharmaceuticals is transforming drug discovery with AI-driven RecursionOS, slashing costs and boosting development speed.
Recursion Pharmaceuticals ( RXRX ) Stock Drops Despite Market Gains: Important Facts to Note
Recursion Pharmaceuticals (RXRX) reached $5.03 at the closing of the latest trading day, reflecting a -6.85% change compared to its last close.
Is the Market Bullish or Bearish on Recursion Pharmaceuticals? - Recursion Pharmaceuticals ( NASDAQ:RXRX )
Recursion Pharmaceuticals's RXRX short percent of float has risen 10.12% since its last report. The company recently reported that it has 120.08 million shares sold short, which is 31.87% of all regular shares that are available for trading.
Recursion Pharmaceuticals ( RXRX ) Declines More Than Market: Some Information for Investors
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $5.03, representing a -1.57% change from its previous close.
Is This Beaten-Down Cathie Wood Artificial Intelligence ( AI ) Stock a Buy?
Recursion Pharmaceuticals ( NASDAQ: RXRX ) is not the most famous artificial intelligence ( AI ) stock on the market, but the biotech ( or techbio ) company has attracted the attention of some big names. Recursion has partnered with the AI juggernaut Nvidia to build a powerful supercomputer, for ...
Why Recursion Pharmaceuticals Was Bouncing Higher on Tuesday
In an effort to save costs and make its financial resources last longer, Recursion Pharmaceuticals ( NASDAQ: RXRX ) is slimming down and streamlining. After the biotech updated its strategy to do so on Tuesday, investors became more hopeful on its future, bidding the stock up.
Recursion Pharmaceuticals Stock Is Up 10% Today: What's Happening? - Recursion Pharmaceuticals ( NASDAQ:RXRX )
Recursion Pharmaceuticals announces a workforce reduction of approximately 20%. The Nvidia-backed company expects the move to extend its cash runway into the fourth quarter of 2027. Get access to the leaderboards pointing to tomorrow's biggest stock movers.
Recursion Pharmaceuticals Stock Surges On Breakthrough AI Model Launch With MIT - Recursion Pharmaceuticals ( NASDAQ:RXRX )
Recursion shares jumped over 18% after launching Boltz-2, a breakthrough AI model with MIT that predicts molecular binding The open-source model significantly accelerates drug discovery, making large-scale virtual screening more practical and cost-effective.
Why Is Zoetis ( ZTS ) Up 8.1% Since Last Earnings Report?
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Recursion Pharmaceuticals ( RXRX ) Up 5.7% Since Last Earnings Report: Can It Continue?
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside?
Recursion Pharmaceuticals and Schrodinger leverage their respective AI drug discovery platforms to potentially develop distinguished therapeutic candidates.
3 Monster Stocks to Hold for the Next 10 Years
A handful of industries are on the verge of explosive growth. These three companies are poised to gain the most.
Recursion Pharmaceuticals Plunges 22% in May: How to Play the Stock
Despite the current downward trend of RXRX, one should retain the stock for long-term gains due to the significant potential of its AI-driven drug discovery technology.
